JP2007517037A - ＲＡＲγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム - Google Patents
ＲＡＲγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム Download PDFInfo
- Publication number
- JP2007517037A JP2007517037A JP2006547316A JP2006547316A JP2007517037A JP 2007517037 A JP2007517037 A JP 2007517037A JP 2006547316 A JP2006547316 A JP 2006547316A JP 2006547316 A JP2006547316 A JP 2006547316A JP 2007517037 A JP2007517037 A JP 2007517037A
- Authority
- JP
- Japan
- Prior art keywords
- carbons
- alkyl
- carbon atoms
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000556 agonist Substances 0.000 title claims abstract description 15
- -1 Disubstituted chalcone oximes Chemical class 0.000 title description 37
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 title 1
- 108091008760 retinoic acid receptors γ Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 230
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 206010014561 Emphysema Diseases 0.000 claims abstract description 15
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 7
- 206010000496 acne Diseases 0.000 claims abstract description 7
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 104
- 125000004432 carbon atom Chemical group C* 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 33
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000004414 alkyl thio group Chemical group 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 16
- 229910052801 chlorine Inorganic materials 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052740 iodine Inorganic materials 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 8
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 8
- 125000005103 alkyl silyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- IXQYPXRYRSEMAA-UHFFFAOYSA-N n-(1,3-diphenylprop-2-enylidene)hydroxylamine Chemical group C=1C=CC=CC=1C(=NO)C=CC1=CC=CC=C1 IXQYPXRYRSEMAA-UHFFFAOYSA-N 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 230000005980 lung dysfunction Effects 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 210000004072 lung Anatomy 0.000 abstract description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 75
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 41
- 239000007787 solid Substances 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- 239000007858 starting material Substances 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000012267 brine Substances 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- 102000003702 retinoic acid receptors Human genes 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 238000003756 stirring Methods 0.000 description 20
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 19
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 18
- 238000007127 saponification reaction Methods 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000003818 flash chromatography Methods 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 13
- 238000001953 recrystallisation Methods 0.000 description 13
- 102000027483 retinoid hormone receptors Human genes 0.000 description 13
- 108091008679 retinoid hormone receptors Proteins 0.000 description 13
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 239000012230 colorless oil Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 239000005457 ice water Substances 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- VYEYYEZHJSOQIG-UHFFFAOYSA-N C=1N=C2C(C)(C)CCC(C)(C)C2=NC=1C(=NO)C=CC1=CC=C(C(O)=O)C=C1 Chemical compound C=1N=C2C(C)(C)CCC(C)(C)C2=NC=1C(=NO)C=CC1=CC=C(C(O)=O)C=C1 VYEYYEZHJSOQIG-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 150000002923 oximes Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- AISXBZVAYNUAKB-UHFFFAOYSA-N 1,1,4,4,6-pentamethyl-2,3-dihydronaphthalene Chemical compound CC1(C)CCC(C)(C)C=2C1=CC(C)=CC=2 AISXBZVAYNUAKB-UHFFFAOYSA-N 0.000 description 5
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 5
- KKNRCYUIPMGPJE-XWVDJSSWSA-N 3-fluoro-4-[(z)-3-hydroxyimino-3-(1,1,3,3-tetramethyl-2h-inden-5-yl)prop-1-enyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CC(C)(C)C2=CC=1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1F KKNRCYUIPMGPJE-XWVDJSSWSA-N 0.000 description 5
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- WKALQROSCJBFLA-UHFFFAOYSA-N 1-(2,2,4,4-tetramethyl-3h-chromen-6-yl)ethanone Chemical compound O1C(C)(C)CC(C)(C)C2=CC(C(=O)C)=CC=C21 WKALQROSCJBFLA-UHFFFAOYSA-N 0.000 description 4
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
- ZLTWIJREHQCJJL-UHFFFAOYSA-N 1-trimethylsilylethanol Chemical compound CC(O)[Si](C)(C)C ZLTWIJREHQCJJL-UHFFFAOYSA-N 0.000 description 4
- WSLBLPPYEJLZAI-NNGYOWHZSA-N 3-fluoro-4-[(z)-3-hydroxyimino-3-(5,8,8-trimethyl-7h-naphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound C=1C=C2C(C)=CCC(C)(C)C2=CC=1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1F WSLBLPPYEJLZAI-NNGYOWHZSA-N 0.000 description 4
- HXZNZRZXGQXLDT-ZKKNQSGNSA-N 4-[(E)-3-hydroxyimino-3-(1,1,3,3-tetramethyl-2H-inden-5-yl)prop-1-enyl]benzoic acid Chemical compound ON=C(/C=C/C1=CC=C(C(=O)O)C=C1)C=1C=C2C(CC(C2=CC1)(C)C)(C)C HXZNZRZXGQXLDT-ZKKNQSGNSA-N 0.000 description 4
- HWOAEEDSSXYQIX-MOTKQCRWSA-N 4-[(z)-3-(8,8-dimethyl-6,7-dihydro-5h-naphthalen-2-yl)-3-hydroxyiminoprop-1-enyl]-3-fluorobenzoic acid Chemical compound C1=C2C(C)(C)CCCC2=CC=C1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1F HWOAEEDSSXYQIX-MOTKQCRWSA-N 0.000 description 4
- HXZNZRZXGQXLDT-HONFWPCWSA-N 4-[(z)-3-hydroxyimino-3-(1,1,3,3-tetramethyl-2h-inden-5-yl)prop-1-enyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CC(C)(C)C2=CC=1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1 HXZNZRZXGQXLDT-HONFWPCWSA-N 0.000 description 4
- YLQLJGMRZTXMTC-UHFFFAOYSA-N 4-[3-hydroxyimino-3-(5,8,8-trimethyl-7h-naphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound C=1C=C2C(C)=CCC(C)(C)C2=CC=1C(=NO)C=CC1=CC=C(C(O)=O)C=C1 YLQLJGMRZTXMTC-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WSLBLPPYEJLZAI-UHFFFAOYSA-N FC=1C=C(C(=O)O)C=CC1C=CC(C1=CC=2C(CC=C(C2C=C1)C)(C)C)=NO Chemical compound FC=1C=C(C(=O)O)C=CC1C=CC(C1=CC=2C(CC=C(C2C=C1)C)(C)C)=NO WSLBLPPYEJLZAI-UHFFFAOYSA-N 0.000 description 4
- KKNRCYUIPMGPJE-UHFFFAOYSA-N FC=1C=C(C(=O)O)C=CC1C=CC(C=1C=C2C(CC(C2=CC1)(C)C)(C)C)=NO Chemical compound FC=1C=C(C(=O)O)C=CC1C=CC(C=1C=C2C(CC(C2=CC1)(C)C)(C)C)=NO KKNRCYUIPMGPJE-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 230000021523 carboxylation Effects 0.000 description 4
- 238000006473 carboxylation reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 4
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- LAJAFFLJAJMYLK-CVOKMOJFSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[[(7s)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N1([C@H]2CCC3=CC=C(C(=C3CC2)OC)NC=2N=C(C(=CN=2)Cl)N[C@H]2[C@H]([C@@]3([H])C[C@@]2(C=C3)[H])C(N)=O)CCOCC1 LAJAFFLJAJMYLK-CVOKMOJFSA-N 0.000 description 3
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- LENAVORGWBTPJR-UHFFFAOYSA-N (5-pyridin-3-ylfuran-2-yl)methanamine Chemical compound O1C(CN)=CC=C1C1=CC=CN=C1 LENAVORGWBTPJR-UHFFFAOYSA-N 0.000 description 3
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 3
- VICOOSNNZUPVHM-IGPZRPDBSA-M (e,3r,5s)-7-[2-(4-fluorophenyl)-4-(3-phenylpentan-3-yl)phenyl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=CC=1C(CC)(CC)C1=CC=CC=C1 VICOOSNNZUPVHM-IGPZRPDBSA-M 0.000 description 3
- XBCVARFSRWLPOC-UHFFFAOYSA-N 1-(1,1,3,3-tetramethyl-2h-inden-5-yl)ethanone Chemical compound CC(=O)C1=CC=C2C(C)(C)CC(C)(C)C2=C1 XBCVARFSRWLPOC-UHFFFAOYSA-N 0.000 description 3
- QZADYGNSQCABPT-UHFFFAOYSA-N 1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C)C(C(=O)C)=C2 QZADYGNSQCABPT-UHFFFAOYSA-N 0.000 description 3
- DHIVJYNSSSHXRG-UHFFFAOYSA-N 1-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethanone Chemical compound S1CCC(C)(C)C2=CC(C(=O)C)=CC=C21 DHIVJYNSSSHXRG-UHFFFAOYSA-N 0.000 description 3
- IHUSZOMIBSDQTB-UHFFFAOYSA-N 1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C=2C1=CC(C(=O)C)=CC=2 IHUSZOMIBSDQTB-UHFFFAOYSA-N 0.000 description 3
- YXIIZVXPGZQGQP-UHFFFAOYSA-N 1-(8,8-dimethyl-6,7-dihydro-5h-naphthalen-2-yl)ethanone Chemical compound C1CCC(C)(C)C2=CC(C(=O)C)=CC=C21 YXIIZVXPGZQGQP-UHFFFAOYSA-N 0.000 description 3
- YCGQPIRMLGEWMW-UHFFFAOYSA-N 1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]-3-[4-[(dimethylamino)methyl]-2,6-di(propan-2-yl)phenyl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN(C)C)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 YCGQPIRMLGEWMW-UHFFFAOYSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 3
- JJDUPJZWDFCRQE-SZVRZUPHSA-N 4-[(E)-3-hydroxyimino-3-(2,2,4,4-tetramethyl-3H-chromen-6-yl)prop-1-enyl]benzoic acid Chemical compound ON=C(/C=C/C1=CC=C(C(=O)O)C=C1)C=1C=C2C(CC(OC2=CC1)(C)C)(C)C JJDUPJZWDFCRQE-SZVRZUPHSA-N 0.000 description 3
- OULUXIQUYQJVFW-NHZXAMDCSA-N 4-[(e)-3-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)-3-hydroxyiminoprop-1-enyl]benzoic acid Chemical compound C1=C2C(C)(C)CCSC2=CC=C1C(=NO)\C=C\C1=CC=C(C(O)=O)C=C1 OULUXIQUYQJVFW-NHZXAMDCSA-N 0.000 description 3
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 3
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 3
- FCBOUJYKAGWYQM-DEOSSOPVSA-N 6-[[(2s)-1-hydroxy-3-phenylpropan-2-yl]amino]-n-(2-phenoxyethyl)-2-(3,4,5-trimethoxyphenyl)pyridine-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=C(N[C@H](CO)CC=3C=CC=CC=3)N=2)C(=O)NCCOC=2C=CC=CC=2)=C1 FCBOUJYKAGWYQM-DEOSSOPVSA-N 0.000 description 3
- VUAGQOMMVXBEDN-UHFFFAOYSA-N 6-bromo-4,4-dimethyl-2,3-dihydro-1h-naphthalene Chemical compound C1=C(Br)C=C2C(C)(C)CCCC2=C1 VUAGQOMMVXBEDN-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 3
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 3
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 3
- 239000007818 Grignard reagent Substances 0.000 description 3
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- AJRQIXBBIDPNGK-BVSLBCMMSA-N benzyl n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(=O)OCC1=CC=CC=C1 AJRQIXBBIDPNGK-BVSLBCMMSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 235000005513 chalcones Nutrition 0.000 description 3
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical group C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125807 compound 37 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- HBEDSQVIWPRPAY-UHFFFAOYSA-N dihydro-benzofuran Natural products C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000004795 grignard reagents Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- SEVSMVUOKAMPDO-UHFFFAOYSA-N para-Acetoxybenzaldehyde Natural products CC(=O)OC1=CC=C(C=O)C=C1 SEVSMVUOKAMPDO-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000030541 receptor transactivation Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 3
- 150000005076 thiochromenes Chemical class 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- JHLIGYPHPBLDDL-UHFFFAOYSA-N (5-pyridin-3-ylthiophen-2-yl)methanamine Chemical compound S1C(CN)=CC=C1C1=CC=CN=C1 JHLIGYPHPBLDDL-UHFFFAOYSA-N 0.000 description 2
- NXRQXRLIGYBVGN-VMPITWQZSA-N (e)-1-(4-bromophenyl)-4-methylpent-1-en-3-one Chemical compound CC(C)C(=O)\C=C\C1=CC=C(Br)C=C1 NXRQXRLIGYBVGN-VMPITWQZSA-N 0.000 description 2
- IWIWGFMIKABCFO-UHFFFAOYSA-N 1,1,3,3-tetramethyl-2h-indene Chemical compound C1=CC=C2C(C)(C)CC(C)(C)C2=C1 IWIWGFMIKABCFO-UHFFFAOYSA-N 0.000 description 2
- BKNUXXFUQHTKHP-UHFFFAOYSA-N 1-(3-methoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(OC)=C2 BKNUXXFUQHTKHP-UHFFFAOYSA-N 0.000 description 2
- TUOWBVGRZCYMGX-UHFFFAOYSA-N 1-(5,5-dimethyl-7,8-dihydro-6h-naphthalen-2-yl)ethanone Chemical compound C1CCC(C)(C)C=2C1=CC(C(=O)C)=CC=2 TUOWBVGRZCYMGX-UHFFFAOYSA-N 0.000 description 2
- HQCCNFFIOWYINW-UHFFFAOYSA-N 1-(5-bromo-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(Br)=CC=C1O HQCCNFFIOWYINW-UHFFFAOYSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- WGABOZPQOOZAOI-UHFFFAOYSA-N 2-[4-[[(3,5-dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid Chemical compound COC1=C(C)C(OC)=CC(C(=O)N(CCCC=2C=CC=CC=2)CC=2C=CC(CC(O)=O)=CC=2)=C1 WGABOZPQOOZAOI-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- BDUBTLFQHNYXPC-UHFFFAOYSA-N 3-methylbut-2-enoyl chloride Chemical compound CC(C)=CC(Cl)=O BDUBTLFQHNYXPC-UHFFFAOYSA-N 0.000 description 2
- JCFWCOHELIPDDU-UHFFFAOYSA-N 4-[3-(1-heptyl-4,4-dimethyl-2-oxo-3h-quinolin-6-yl)-3-oxoprop-1-enyl]benzoic acid Chemical compound C=1C=C2N(CCCCCCC)C(=O)CC(C)(C)C2=CC=1C(=O)C=CC1=CC=C(C(O)=O)C=C1 JCFWCOHELIPDDU-UHFFFAOYSA-N 0.000 description 2
- KGSDQDYFUNSZEL-UHFFFAOYSA-N 4-[3-(8,8-dimethyl-6,7-dihydro-5H-naphthalen-2-yl)-3-oxoprop-1-enyl]-3-fluorobenzoic acid Chemical compound C1=C2C(C)(C)CCCC2=CC=C1C(=O)C=CC1=CC=C(C(O)=O)C=C1F KGSDQDYFUNSZEL-UHFFFAOYSA-N 0.000 description 2
- RWYDGFDBOCXFTA-UHFFFAOYSA-N 4-[3-oxo-3-(1,1,3,3-tetramethyl-2h-inden-5-yl)prop-1-enyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CC(C)(C)C2=CC=1C(=O)C=CC1=CC=C(C(O)=O)C=C1 RWYDGFDBOCXFTA-UHFFFAOYSA-N 0.000 description 2
- ZXQHMEUGMCXKLO-KPKJPENVSA-N 4-[3-oxo-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(=O)\C=C\C1=CC=C(C(O)=O)C=C1 ZXQHMEUGMCXKLO-KPKJPENVSA-N 0.000 description 2
- FTBCOQFMQSTCQQ-UHFFFAOYSA-N 4-bromobenzenethiol Chemical compound SC1=CC=C(Br)C=C1 FTBCOQFMQSTCQQ-UHFFFAOYSA-N 0.000 description 2
- PFDVPCSDZXZDMF-UHFFFAOYSA-N 4-methyl-4-phenylpentan-2-one Chemical compound CC(=O)CC(C)(C)C1=CC=CC=C1 PFDVPCSDZXZDMF-UHFFFAOYSA-N 0.000 description 2
- KBNYHSUVFVLCTA-UHFFFAOYSA-N 6-acetyl-1-heptyl-4,4-dimethyl-3h-quinolin-2-one Chemical compound CC(=O)C1=CC=C2N(CCCCCCC)C(=O)CC(C)(C)C2=C1 KBNYHSUVFVLCTA-UHFFFAOYSA-N 0.000 description 2
- OTVKXYCZLMHXQS-UHFFFAOYSA-N 6-acetyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=CC(C(=O)C)=CC=C21 OTVKXYCZLMHXQS-UHFFFAOYSA-N 0.000 description 2
- FTRFIBKHXWYJAW-UHFFFAOYSA-N 6-bromo-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(Br)C=C2C(C)(C)CC(=O)NC2=C1 FTRFIBKHXWYJAW-UHFFFAOYSA-N 0.000 description 2
- HWRLTYBJEKHTJG-UHFFFAOYSA-N 6-bromo-4,4-dimethyl-2,3-dihydronaphthalen-1-one Chemical compound C1=C(Br)C=C2C(C)(C)CCC(=O)C2=C1 HWRLTYBJEKHTJG-UHFFFAOYSA-N 0.000 description 2
- KLPXHMKJEIFOOS-UHFFFAOYSA-N 6-methoxy-1,1,4,4-tetramethyl-2,3-dihydronaphthalene Chemical compound CC1(C)CCC(C)(C)C=2C1=CC(OC)=CC=2 KLPXHMKJEIFOOS-UHFFFAOYSA-N 0.000 description 2
- YKFMBFCYRIPYJJ-UHFFFAOYSA-N 7-bromo-1,1,4-trimethyl-2h-naphthalene Chemical compound BrC1=CC=C2C(C)=CCC(C)(C)C2=C1 YKFMBFCYRIPYJJ-UHFFFAOYSA-N 0.000 description 2
- IWVTVUANDUIMMI-UHFFFAOYSA-N 7-bromo-4,4-dimethyl-2,3-dihydro-1h-naphthalene Chemical compound BrC1=CC=C2C(C)(C)CCCC2=C1 IWVTVUANDUIMMI-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- WUZBOJXXYMKMMF-UHFFFAOYSA-N COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F Chemical compound COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F WUZBOJXXYMKMMF-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- 238000005882 aldol condensation reaction Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 2
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 150000008371 chromenes Chemical class 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126212 compound 17a Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 238000000670 ligand binding assay Methods 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BJPQRVCCAISNSI-UHFFFAOYSA-N n-(4-bromophenyl)-3-methylbut-2-enamide Chemical compound CC(C)=CC(=O)NC1=CC=C(Br)C=C1 BJPQRVCCAISNSI-UHFFFAOYSA-N 0.000 description 2
- DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QSUJAUYJBJRLKV-UHFFFAOYSA-M tetraethylazanium;fluoride Chemical compound [F-].CC[N+](CC)(CC)CC QSUJAUYJBJRLKV-UHFFFAOYSA-M 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical group C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- CCQKWSZYTOCEIB-UHFFFAOYSA-N 1,1,4,4-tetramethyl-2,3-dihydronaphthalene Chemical compound C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 CCQKWSZYTOCEIB-UHFFFAOYSA-N 0.000 description 1
- OZXIZRZFGJZWBF-UHFFFAOYSA-N 1,3,5-trimethyl-2-(2,4,6-trimethylphenoxy)benzene Chemical compound CC1=CC(C)=CC(C)=C1OC1=C(C)C=C(C)C=C1C OZXIZRZFGJZWBF-UHFFFAOYSA-N 0.000 description 1
- CMFGVGPIABQTCV-UHFFFAOYSA-N 1-(5,5,8,8-tetramethyl-6,7-dihydroquinoxalin-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C=2C1=NC(C(=O)C)=CN=2 CMFGVGPIABQTCV-UHFFFAOYSA-N 0.000 description 1
- CLCKEYDUIYBAND-UHFFFAOYSA-N 1-(5,8,8-trimethyl-7h-naphthalen-2-yl)ethanone Chemical compound CC1=CCC(C)(C)C2=CC(C(=O)C)=CC=C21 CLCKEYDUIYBAND-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- LMHCYRULPLGEEZ-UHFFFAOYSA-N 1-iodoheptane Chemical compound CCCCCCCI LMHCYRULPLGEEZ-UHFFFAOYSA-N 0.000 description 1
- CKZPCBSCILYZCP-UHFFFAOYSA-N 2,2-dimethylthiochromene Chemical compound C1=CC=C2C=CC(C)(C)SC2=C1 CKZPCBSCILYZCP-UHFFFAOYSA-N 0.000 description 1
- WGSMVIHKBMAWRN-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1-benzofuran Chemical compound C1C=CC=C2OCCC21 WGSMVIHKBMAWRN-UHFFFAOYSA-N 0.000 description 1
- KELIOZMTDOSCMM-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1-benzothiophene Chemical compound C1C=CC=C2SCCC21 KELIOZMTDOSCMM-UHFFFAOYSA-N 0.000 description 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical group C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical class C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- OHXAOPZTJOUYKM-UHFFFAOYSA-N 3-Chloro-2-methylpropene Chemical compound CC(=C)CCl OHXAOPZTJOUYKM-UHFFFAOYSA-N 0.000 description 1
- OUAZPCKRSSEQKB-UHFFFAOYSA-N 3-bromo-2-fluorobenzaldehyde Chemical compound FC1=C(Br)C=CC=C1C=O OUAZPCKRSSEQKB-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- XNDRXENBJCSNBS-CHIGLPARSA-N 3-fluoro-4-[(z)-3-hydroxyimino-3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1F XNDRXENBJCSNBS-CHIGLPARSA-N 0.000 description 1
- HIMLMQBUDUGPQS-SSQZMFIFSA-N 4-[(E)-3-hydroxyimino-3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound ON=C(/C=C/C1=CC=C(C(=O)O)C=C1)C1=CC=2C(CCC(C2C=C1C)(C)C)(C)C HIMLMQBUDUGPQS-SSQZMFIFSA-N 0.000 description 1
- CEMFDOVHEOYETE-GFXZSFKNSA-N 4-[(E)-3-hydroxyimino-3-(3-methoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound ON=C(/C=C/C1=CC=C(C(=O)O)C=C1)C1=CC=2C(CCC(C2C=C1OC)(C)C)(C)C CEMFDOVHEOYETE-GFXZSFKNSA-N 0.000 description 1
- DKMAOOMRQCCGEO-DKEAAGQRSA-N 4-[(E)-3-hydroxyimino-3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound C(=O)(O)C1=CC=C(C=C1)/C=C/C(=NO)C1=CC=2C(CCC(C2C=C1)(C)C)(C)C DKMAOOMRQCCGEO-DKEAAGQRSA-N 0.000 description 1
- YLQLJGMRZTXMTC-LUSVTQLDSA-N 4-[(E)-3-hydroxyimino-3-(5,8,8-trimethyl-7H-naphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound ON=C(/C=C/C1=CC=C(C(=O)O)C=C1)C1=CC=2C(CC=C(C2C=C1)C)(C)C YLQLJGMRZTXMTC-LUSVTQLDSA-N 0.000 description 1
- RTPKIOAUMUMUBV-ZQFZOQMHSA-N 4-[(e)-3-(1-heptyl-4,4-dimethyl-2-oxo-3h-quinolin-6-yl)-3-hydroxyiminoprop-1-enyl]benzoic acid Chemical compound C=1C=C2N(CCCCCCC)C(=O)CC(C)(C)C2=CC=1C(=NO)\C=C\C1=CC=C(C(O)=O)C=C1 RTPKIOAUMUMUBV-ZQFZOQMHSA-N 0.000 description 1
- SHPDCSICIQGOQI-VNCKWFGWSA-N 4-[(e)-3-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)-3-hydroxyiminoprop-1-enyl]-3-fluorobenzoic acid Chemical compound C1=C2C(C)(C)CCSC2=CC=C1C(=NO)\C=C\C1=CC=C(C(O)=O)C=C1F SHPDCSICIQGOQI-VNCKWFGWSA-N 0.000 description 1
- HWOAEEDSSXYQIX-NWDPKIKOSA-N 4-[(e)-3-(8,8-dimethyl-6,7-dihydro-5h-naphthalen-2-yl)-3-hydroxyiminoprop-1-enyl]-3-fluorobenzoic acid Chemical compound C1=C2C(C)(C)CCCC2=CC=C1C(=NO)\C=C\C1=CC=C(C(O)=O)C=C1F HWOAEEDSSXYQIX-NWDPKIKOSA-N 0.000 description 1
- PWKJRHAJVIRIER-GYSSSCHMSA-N 4-[(e)-3-(8,8-dimethyl-6,7-dihydro-5h-naphthalen-2-yl)-3-hydroxyiminoprop-1-enyl]benzoic acid Chemical compound C1=C2C(C)(C)CCCC2=CC=C1C(=NO)\C=C\C1=CC=C(C(O)=O)C=C1 PWKJRHAJVIRIER-GYSSSCHMSA-N 0.000 description 1
- SHPDCSICIQGOQI-UPPABOTBSA-N 4-[(z)-3-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)-3-hydroxyiminoprop-1-enyl]-3-fluorobenzoic acid Chemical compound C1=C2C(C)(C)CCSC2=CC=C1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1F SHPDCSICIQGOQI-UPPABOTBSA-N 0.000 description 1
- OULUXIQUYQJVFW-DPXLWQDTSA-N 4-[(z)-3-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)-3-hydroxyiminoprop-1-enyl]benzoic acid Chemical compound C1=C2C(C)(C)CCSC2=CC=C1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1 OULUXIQUYQJVFW-DPXLWQDTSA-N 0.000 description 1
- WIUUNXKUGIEUHQ-YJMQHBMXSA-N 4-[(z)-3-(5,5-dimethyl-7,8-dihydro-6h-naphthalen-2-yl)-3-hydroxyiminoprop-1-enyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCCC2=CC=1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1 WIUUNXKUGIEUHQ-YJMQHBMXSA-N 0.000 description 1
- PWKJRHAJVIRIER-YJMQHBMXSA-N 4-[(z)-3-(8,8-dimethyl-6,7-dihydro-5h-naphthalen-2-yl)-3-hydroxyiminoprop-1-enyl]benzoic acid Chemical compound C1=C2C(C)(C)CCCC2=CC=C1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1 PWKJRHAJVIRIER-YJMQHBMXSA-N 0.000 description 1
- CEMFDOVHEOYETE-QKLNDCERSA-N 4-[(z)-3-hydroxyimino-3-(3-methoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound COC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=NO)\C=C/C1=CC=C(C(O)=O)C=C1 CEMFDOVHEOYETE-QKLNDCERSA-N 0.000 description 1
- RTPKIOAUMUMUBV-UHFFFAOYSA-N 4-[3-(1-heptyl-4,4-dimethyl-2-oxo-3h-quinolin-6-yl)-3-hydroxyiminoprop-1-enyl]benzoic acid Chemical compound C=1C=C2N(CCCCCCC)C(=O)CC(C)(C)C2=CC=1C(=NO)C=CC1=CC=C(C(O)=O)C=C1 RTPKIOAUMUMUBV-UHFFFAOYSA-N 0.000 description 1
- WIUUNXKUGIEUHQ-UHFFFAOYSA-N 4-[3-(5,5-dimethyl-7,8-dihydro-6h-naphthalen-2-yl)-3-hydroxyiminoprop-1-enyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCCC2=CC=1C(=NO)C=CC1=CC=C(C(O)=O)C=C1 WIUUNXKUGIEUHQ-UHFFFAOYSA-N 0.000 description 1
- UPCARQPLANFGQJ-UHFFFAOYSA-N 4-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC(Br)=CC=C1C=O UPCARQPLANFGQJ-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- MRGBBKQOSUHKPF-UHFFFAOYSA-N 4-bromofuran-2-carbaldehyde Chemical compound BrC1=COC(C=O)=C1 MRGBBKQOSUHKPF-UHFFFAOYSA-N 0.000 description 1
- PDONIKHDXYHTLS-UHFFFAOYSA-N 4-bromothiophene-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=C1 PDONIKHDXYHTLS-UHFFFAOYSA-N 0.000 description 1
- ATKBXDWWYAJUDR-UHFFFAOYSA-N 5-bromo-3,3-dimethyl-3a,4-dihydro-2h-1-benzofuran Chemical compound C1=C(Br)CC2C(C)(C)COC2=C1 ATKBXDWWYAJUDR-UHFFFAOYSA-N 0.000 description 1
- WJTFHWXMITZNHS-UHFFFAOYSA-N 5-bromofuran-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)O1 WJTFHWXMITZNHS-UHFFFAOYSA-N 0.000 description 1
- RFBLXLCJCJMOCN-UHFFFAOYSA-N 5-bromonaphthalene-1-carbaldehyde Chemical compound C1=CC=C2C(Br)=CC=CC2=C1C=O RFBLXLCJCJMOCN-UHFFFAOYSA-N 0.000 description 1
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 1
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- KMLKUNVLSWKFLA-UHFFFAOYSA-N 6-bromo-2,2-dimethyl-3h-chromen-4-one Chemical compound BrC1=CC=C2OC(C)(C)CC(=O)C2=C1 KMLKUNVLSWKFLA-UHFFFAOYSA-N 0.000 description 1
- KVPMXEMODNMSMM-UHFFFAOYSA-N 6-bromo-2,2-dimethyl-3h-thiochromen-4-one Chemical compound BrC1=CC=C2SC(C)(C)CC(=O)C2=C1 KVPMXEMODNMSMM-UHFFFAOYSA-N 0.000 description 1
- FHBXFINOQUIMDK-UHFFFAOYSA-N 6-bromo-2,2-dimethylchromene Chemical class C1=C(Br)C=C2C=CC(C)(C)OC2=C1 FHBXFINOQUIMDK-UHFFFAOYSA-N 0.000 description 1
- SZJGNFZZXCBDEY-UHFFFAOYSA-N 6-bromo-2,2-dimethylthiochromene Chemical class C1=C(Br)C=C2C=CC(C)(C)SC2=C1 SZJGNFZZXCBDEY-UHFFFAOYSA-N 0.000 description 1
- FLNJCJQFSGXLIR-UHFFFAOYSA-N 6-bromo-4,4-dimethyl-2,3-dihydrothiochromene Chemical compound C1=C(Br)C=C2C(C)(C)CCSC2=C1 FLNJCJQFSGXLIR-UHFFFAOYSA-N 0.000 description 1
- QWFHFNGMCPMOCD-UHFFFAOYSA-N 6-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=CC(C=O)=N1 QWFHFNGMCPMOCD-UHFFFAOYSA-N 0.000 description 1
- DMEAYYYHWLCPCD-UHFFFAOYSA-N 7-bromo-2,3-dihydrochromen-4-one Chemical compound O=C1CCOC2=CC(Br)=CC=C21 DMEAYYYHWLCPCD-UHFFFAOYSA-N 0.000 description 1
- JVHFFCUGCPOSIF-UHFFFAOYSA-N 7-bromo-2,3-dihydrothiochromen-4-one Chemical compound O=C1CCSC2=CC(Br)=CC=C21 JVHFFCUGCPOSIF-UHFFFAOYSA-N 0.000 description 1
- QZSBQGIPLDEDIX-UHFFFAOYSA-N 7-bromo-4,4-dimethyl-2,3-dihydronaphthalen-1-one Chemical compound BrC1=CC=C2C(C)(C)CCC(=O)C2=C1 QZSBQGIPLDEDIX-UHFFFAOYSA-N 0.000 description 1
- 206010000503 Acne cystic Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- XNDRXENBJCSNBS-UHFFFAOYSA-N FC=1C=C(C(=O)O)C=CC1C=CC(C1=CC=2C(CCC(C2C=C1)(C)C)(C)C)=NO Chemical compound FC=1C=C(C(=O)O)C=CC1C=CC(C1=CC=2C(CCC(C2C=C1)(C)C)(C)C)=NO XNDRXENBJCSNBS-UHFFFAOYSA-N 0.000 description 1
- 238000005618 Fries rearrangement reaction Methods 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001788 chalcone derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- OBDGHGCVJLFIBI-UHFFFAOYSA-N ethyl 4-[3-(5,5-dimethyl-7,8-dihydro-6h-naphthalen-2-yl)-3-oxoprop-1-enyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C=CC(=O)C1=CC=C2C(C)(C)CCCC2=C1 OBDGHGCVJLFIBI-UHFFFAOYSA-N 0.000 description 1
- AWQRMUYSBYTJCE-UHFFFAOYSA-N ethyl 4-[3-(8,8-dimethyl-6,7-dihydro-5h-naphthalen-2-yl)-3-oxoprop-1-enyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C=CC(=O)C1=CC=C(CCCC2(C)C)C2=C1 AWQRMUYSBYTJCE-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- SHOJXDKTYKFBRD-UHFFFAOYSA-N mesityl oxide Natural products CC(C)=CC(C)=O SHOJXDKTYKFBRD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- CFMGPKZYEUOERS-UHFFFAOYSA-N methyl 2-fluoro-4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1F CFMGPKZYEUOERS-UHFFFAOYSA-N 0.000 description 1
- UVSBCUAQEZINCQ-UHFFFAOYSA-N methyl 3-formylbenzoate Chemical compound COC(=O)C1=CC=CC(C=O)=C1 UVSBCUAQEZINCQ-UHFFFAOYSA-N 0.000 description 1
- KDPOOUQFAUOHHX-UHFFFAOYSA-N methyl 5-formylfuran-2-carboxylate Chemical compound COC(=O)C1=CC=C(C=O)O1 KDPOOUQFAUOHHX-UHFFFAOYSA-N 0.000 description 1
- RKSNUGDDGDFSRP-UHFFFAOYSA-N methyl 5-formylfuran-3-carboxylate Chemical compound COC(=O)C1=COC(C=O)=C1 RKSNUGDDGDFSRP-UHFFFAOYSA-N 0.000 description 1
- APNKWEPRZUSZCJ-UHFFFAOYSA-N methyl 5-formylthiophene-2-carboxylate Chemical compound COC(=O)C1=CC=C(C=O)S1 APNKWEPRZUSZCJ-UHFFFAOYSA-N 0.000 description 1
- GNXNZRYWBFMVHK-UHFFFAOYSA-N methyl 5-formylthiophene-3-carboxylate Chemical compound COC(=O)C1=CSC(C=O)=C1 GNXNZRYWBFMVHK-UHFFFAOYSA-N 0.000 description 1
- CERBENZCBVYKEF-UHFFFAOYSA-N methyl 6-formylpyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C=O)=N1 CERBENZCBVYKEF-UHFFFAOYSA-N 0.000 description 1
- BZOWIADSJYMJJJ-UHFFFAOYSA-N methyl 6-formylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(C=O)N=C1 BZOWIADSJYMJJJ-UHFFFAOYSA-N 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 102000027478 retinoid receptor subtypes Human genes 0.000 description 1
- 108091008678 retinoid receptor subtypes Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53373303P | 2003-12-30 | 2003-12-30 | |
| PCT/US2004/043148 WO2005066116A1 (en) | 2003-12-30 | 2004-12-21 | Disubstituted chalcone oximes as selective agonists of rarϝ retinoid receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517037A true JP2007517037A (ja) | 2007-06-28 |
| JP2007517037A5 JP2007517037A5 (https=) | 2008-02-14 |
Family
ID=34748950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547316A Pending JP2007517037A (ja) | 2003-12-30 | 2004-12-21 | ＲＡＲγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7476673B2 (https=) |
| EP (1) | EP1704139A1 (https=) |
| JP (1) | JP2007517037A (https=) |
| CA (1) | CA2552090A1 (https=) |
| MX (1) | MXPA06007560A (https=) |
| WO (1) | WO2005066116A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010092771A1 (ja) * | 2009-02-10 | 2010-08-19 | 日本曹達株式会社 | 含窒素化合物および有害生物防除剤 |
| WO2017043616A1 (ja) * | 2015-09-10 | 2017-03-16 | 国立大学法人 岡山大学 | 炎症性呼吸器疾患の予防又は治療用医薬組成物 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2881137B1 (fr) * | 2005-01-27 | 2007-03-02 | Servier Lab | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2008112483A2 (en) * | 2007-03-09 | 2008-09-18 | Sanofi-Aventis | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof |
| CN101941919B (zh) * | 2009-07-07 | 2014-07-02 | 天津药物研究院 | 一种制备顺式肟及肟醚衍生物的方法 |
| GB0915523D0 (en) | 2009-09-07 | 2009-10-07 | Genome Res Ltd | Cells and methods for obtaining them |
| AR078171A1 (es) | 2009-09-15 | 2011-10-19 | Sanofi Aventis | Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas |
| MX2012006776A (es) | 2009-12-14 | 2012-10-05 | Merck Patent Gmbh | Inhibidores de la esfingosina quinasa. |
| CA2784647A1 (en) | 2009-12-17 | 2011-07-14 | Merck Patent Gmbh | Inhibitors of sphingosine kinase |
| EP3380086B1 (en) | 2015-11-25 | 2021-10-13 | IO Therapeutics, Inc. | Cyp26-resistant rar-alpha selective agonists in the treatment of cancer |
| TW201906816A (zh) | 2017-07-06 | 2019-02-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚甲醯胺類衍生物、其製備方法及其在醫藥上的應用 |
| WO2019014468A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY |
| US10363272B2 (en) | 2017-08-31 | 2019-07-30 | Io Therapeutics, Inc. | RAR selective agonists in combination with immune modulators for cancer immunotherapy |
| EP3683206A4 (en) | 2017-09-12 | 2021-01-13 | Jiangsu Hengrui Medicine Co., Ltd. | DEUTERIUM ATOM SUBSTITUTED INDOLFORMAMIDE DERIVATIVE, MANUFACTURING METHOD FOR ITS AND MEDICAL APPLICATIONS THEREOF |
| CA3077331A1 (en) | 2017-09-28 | 2019-04-04 | Johnson & Johnson Consumer Inc. | Cosmetic compositions and method of treating the skin |
| CN112142745B (zh) * | 2019-06-27 | 2023-03-21 | 杭州和正医药有限公司 | 一种酪蛋白激酶1ε抑制剂、药物组合物及其应用 |
| WO2023097259A1 (en) * | 2021-11-23 | 2023-06-01 | Io Therapeutics, Inc. | METHODS OF USING RARγ AGONISTS FOR CANCER TREATMENT |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002526534A (ja) * | 1998-10-01 | 2002-08-20 | アラーガン・セイルズ・インコーポレイテッド | レチノイドｘ受容体に選択的な活性を有するテトラヒドロキノリン誘導体 |
| JP2003519103A (ja) * | 1999-12-15 | 2003-06-17 | アラーガン、インコーポレイテッド | 軟骨と骨の病状の処置におけるレチノイド受容体アンタゴニストの使用 |
| JP2004532239A (ja) * | 2001-05-03 | 2004-10-21 | アラーガン、インコーポレイテッド | 高脂質血症の処置方法 |
| JP2007518719A (ja) * | 2003-12-26 | 2007-07-12 | アラーガン インコーポレイテッド | ＲＡＲγレチノイド受容体アンタゴニスト活性を有する二置換カルコンオキシム |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4001618B2 (ja) | 1991-12-18 | 2007-10-31 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | レチノイド受容体によって仲介される過程の修飾方法およびそれに有用な化合物 |
| US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
| WO1996011210A1 (en) * | 1994-10-07 | 1996-04-18 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic hexapeptides having antibiotic activity |
| US5599967A (en) * | 1994-12-29 | 1997-02-04 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity |
| US6008204A (en) * | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5723666A (en) * | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| US5739338A (en) * | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
| US5760276A (en) * | 1997-03-06 | 1998-06-02 | Allergan | Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
| US6037488A (en) * | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
| US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| AU4228000A (en) * | 1999-04-14 | 2000-11-14 | Allergan Sales, Inc. | Methods and compositions for the treatment and prevention of lung disease |
| US6403810B2 (en) * | 2000-07-10 | 2002-06-11 | Hoffmann-La Roche Inc. | Thiophene derivatives |
| US6303785B1 (en) * | 2000-08-29 | 2001-10-16 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
| SI1324970T1 (sl) | 2000-10-02 | 2009-02-28 | Hoffmann La Roche | Retinoidi za zdravljenje emfizema |
| US20030003517A1 (en) | 2001-03-22 | 2003-01-02 | Klein Elliott S. | Methods of detecting dissociated nuclear hormone receptor ligands |
-
2004
- 2004-12-17 US US11/015,994 patent/US7476673B2/en not_active Expired - Fee Related
- 2004-12-21 JP JP2006547316A patent/JP2007517037A/ja active Pending
- 2004-12-21 EP EP04815251A patent/EP1704139A1/en not_active Withdrawn
- 2004-12-21 CA CA002552090A patent/CA2552090A1/en not_active Abandoned
- 2004-12-21 WO PCT/US2004/043148 patent/WO2005066116A1/en not_active Ceased
- 2004-12-21 MX MXPA06007560A patent/MXPA06007560A/es not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002526534A (ja) * | 1998-10-01 | 2002-08-20 | アラーガン・セイルズ・インコーポレイテッド | レチノイドｘ受容体に選択的な活性を有するテトラヒドロキノリン誘導体 |
| JP2003519103A (ja) * | 1999-12-15 | 2003-06-17 | アラーガン、インコーポレイテッド | 軟骨と骨の病状の処置におけるレチノイド受容体アンタゴニストの使用 |
| JP2004532239A (ja) * | 2001-05-03 | 2004-10-21 | アラーガン、インコーポレイテッド | 高脂質血症の処置方法 |
| JP2007518719A (ja) * | 2003-12-26 | 2007-07-12 | アラーガン インコーポレイテッド | ＲＡＲγレチノイド受容体アンタゴニスト活性を有する二置換カルコンオキシム |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010092771A1 (ja) * | 2009-02-10 | 2010-08-19 | 日本曹達株式会社 | 含窒素化合物および有害生物防除剤 |
| US8222420B2 (en) | 2009-02-10 | 2012-07-17 | Nippon Soda Co., Ltd. | Nitrogen-containing compounds and harmful organism control agents |
| WO2017043616A1 (ja) * | 2015-09-10 | 2017-03-16 | 国立大学法人 岡山大学 | 炎症性呼吸器疾患の予防又は治療用医薬組成物 |
| JPWO2017043616A1 (ja) * | 2015-09-10 | 2018-06-28 | 国立大学法人 岡山大学 | 炎症性呼吸器疾患の予防又は治療用医薬組成物 |
| US11026932B2 (en) | 2015-09-10 | 2021-06-08 | National University Corporation Okayama University | Medicinal composition for preventing or treating inflammatory respiratory disease |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1704139A1 (en) | 2006-09-27 |
| MXPA06007560A (es) | 2006-08-31 |
| WO2005066116A1 (en) | 2005-07-21 |
| US7476673B2 (en) | 2009-01-13 |
| CA2552090A1 (en) | 2005-07-21 |
| US20050148590A1 (en) | 2005-07-07 |
| WO2005066116A8 (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517037A (ja) | ＲＡＲγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム | |
| JP4072208B2 (ja) | レチノイド作動剤、拮抗剤または逆作動剤型の生物学的活性を有する三置換フェニル誘導体 | |
| EP1117628B1 (en) | 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors | |
| JP4052668B2 (ja) | レチノイド様生物学的活性を有する２，４−ペンタジエン酸誘導体 | |
| JPH03120273A (ja) | レチノイド様活性を有するジ置換アセチレン | |
| EP0273451B1 (en) | Lipoxygenase inhibitory compounds | |
| JP2001504458A (ja) | レチノイド受容体に対し作動剤、拮抗剤または逆作動剤型活性を有するｎ―アリール置換テトラヒドロキノリンリガンド | |
| JPH0794407B2 (ja) | レチノイド様活性を有する化合物およびそれを含有する薬剤組成物 | |
| JP2002526534A (ja) | レチノイドｘ受容体に選択的な活性を有するテトラヒドロキノリン誘導体 | |
| JP2003507369A (ja) | レチノイド様生物学的活性を有するテトラヒドロキノリン誘導体 | |
| US20030166932A1 (en) | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | |
| JP2001505914A (ja) | レチノイド拮抗剤またはレチノイド逆作動剤型の生物学的活性を有する、アリールまたはヘテロアリール置換３，４−ジヒドロアントラセン、並びにアリールまたはヘテロアリール置換ベンゾ［１，２−ｇ］−クロマ−３−エン、ベンゾ［１，２−ｇ］−チオクロマ−３−エンおよびベンゾ［１，２−ｇ］−１，２−ジヒドロキノリン誘導体 | |
| US7026487B2 (en) | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity | |
| US7432388B2 (en) | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | |
| US6403638B1 (en) | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | |
| US6759546B1 (en) | 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity | |
| US6388105B1 (en) | Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | |
| CA1249834A (fr) | Preparation d'acides dihydro-5,6-4h-cyclopenta ¬b|thiophenecarboxyliques-6 | |
| US6759547B1 (en) | 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity | |
| US6620963B1 (en) | TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY | |
| HK1039477B (en) | 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071218 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20100907 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101206 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101213 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110322 |